Tomasek
Aaron Tomasek, Wooster, OH US
Patent application number | Description | Published |
---|---|---|
20090294325 | Reduced Puffing Needle Coke From Coal Tar - A reduced puffing needle coke is formed, which includes a lesser amount of nitrogen within the coke so that carbon articles produced from such coke experience minimal expansion upon heating to graphitization temperatures. | 12-03-2009 |
20090294326 | Reduced Puffing Needle Coke From Coal Tar Distillate - A reduced puffing needle coke is formed, which includes a reduced nitrogen content within the coke so that the coke particles do not experience as much puffing during the formation of graphitized carbon articles produced from such coke upon heating to graphitization temperatures. | 12-03-2009 |
20090294327 | Reduced Puffing Needle Coke From Decant Oil - A reduced puffing needle coke is formed from decant oil, which includes a lesser amount of nitrogen within the coke so that carbon articles produced from such coke experience minimal expansion upon heating to graphitization temperatures. | 12-03-2009 |
20110274136 | Reduced Puffing Needle Coke From Coal Tar - A reduced puffing needle coke is formed, which includes a lesser amount of nitrogen within the coke so that carbon articles produced from such coke experience minimal expansion upon heating to graphitization temperatures. | 11-10-2011 |
20110280274 | Reduced Puffing Needle Coke From Decant Oil - A reduced puffing needle coke is formed from decant oil, which includes a lesser amount of nitrogen within the coke so that carbon articles produced from such coke experience minimal expansion upon heating to graphitization temperatures. | 11-17-2011 |
20110280275 | Reduced Puffing Needle Coke From Coal Tar Distillate - A reduced puffing needle coke is formed, which includes a reduced nitrogen content within the coke so that the coke particles do not experience as much puffing during the formation of graphitized carbon articles produced from such coke upon heating to graphitization temperatures. | 11-17-2011 |
20130012744 | Reduced Puffing Needle Coke From Coal Tar Distillate - A reduced puffing needle coke is formed, which includes a reduced nitrogen content within the coke so that the coke particles do not experience as much puffing during the formation of graphitized carbon articles produced from such coke upon heating to graphitization temperatures. | 01-10-2013 |
Aaron Tomasek, Lodi, OH US
Patent application number | Description | Published |
---|---|---|
20130148686 | GRAPHITE ELECTRODE - A graphite electrode exhibits oxidation resistance by modifying the outer radial surface characteristics. The outer radial surface may be modified by providing a textured portion which improves water flow while minimizing water absorbtion. Alternately, a layer of flexible graphite or plurality of particles of exfoliated graphite may be disposed on the outer radial surface of the electrode body. | 06-13-2013 |
20130171453 | Graphite Electrodes - A carbon article having a first zone and a second zone wherein in the first zone formed from a first mix design and the second zone formed from a second mix design and the first and second mix designs have at least one difference selected from the group of differences of a presence of a certain material, a concentration of a certain material, the size of the a certain material and combinations thereof. | 07-04-2013 |
20130279534 | Graphite Electrodes - A graphite electrode exhibits oxidation resistance by modifying the outer radial surface characteristics. The outer radial surface may be modified by providing a textured portion which improves water flow while minimizing water absorbtion. Alternately, a layer of flexible graphite or plurality of particles of exfoliated graphite may be disposed on the outer radial surface of the electrode body. | 10-24-2013 |
Charles Tomasek, Rochester, MN US
Patent application number | Description | Published |
---|---|---|
20150174371 | SYSTEM FOR BYPASSING VASCULAR OCCLUSION HAVING PUNCTURING MECHANISM AND METHOD - A system for bypassing a vascular occlusion includes a catheter, and a puncturing mechanism within the catheter having a sleeve and a puncture wire positioned within the sleeve. The puncture wire is elastically deformable between an access configuration, and a deployed configuration. The puncture wire has a shape memory bias and is retracted within the sleeve and held by the sleeve in opposition to the bias in the access configuration. | 06-25-2015 |
Edward Tomasek, Costa Mesa, CA US
Patent application number | Description | Published |
---|---|---|
20110220285 | METHODS AND SYSTEMS FOR TEXTURING CERAMIC COMPONENTS - Embodiments of the present invention provide methods for forming a hardened and roughened ceramic component. Specific steps include forming a sintered ceramic component, texturing the surface of the sintered ceramic component, and firing the component to harden it. The resulting ceramic component may have a textured surface, and in a specific embodiment, the textured surface has a roughness of about 100 to about 2000 μin Ra. | 09-15-2011 |
Kevin A. Tomasek, Zeeland, MI US
Patent application number | Description | Published |
---|---|---|
20100219014 | COMPOSITE HEADLINER WITH IMPROVED ACOUSTIC PERFORMANCE - A composite headliner material allows sound waves originating within a vehicle to penetrate deeply into the headliner where all of a significant portion of their energy is absorbed rather than reflected back into the vehicle. The coverstock sheet is backed by a multilayer material with a foam core coated above and below by a fibrous glass mat impregnated with an adhesive with scrim layers above and below glass mat layers. | 09-02-2010 |
20110133522 | VEHICLE PANEL - A vehicle panel with a folded-over or wrapped edge is disclosed. The vehicle panel comprises a main body portion. The main body portion includes a first layer and a second layer. The first layer is formed of a substantially rigid material and has a first surface, a second surface and an edge. The second layer is coupled to the second surface of the first layer and formed of a substantially flexible material. The vehicle panel also comprises a flap integrally formed with the main body portion at the edge and comprises at least the second layer. The vehicle panel further comprises a hinge separating the flap from the main body portion, the hinge is defined by at least a portion of the first layer having a reduced thickness. The flap is folded back about the hinge towards the first surface of the first layer to substantially conceal the edge. | 06-09-2011 |
20140333097 | VEHICLE PANEL - A vehicle panel with a folded-over or wrapped edge is disclosed. The vehicle panel comprises a main body portion. The main body portion includes a first layer and a second layer. The first layer is formed of a substantially rigid material and has a first surface, a second surface and an edge. The second layer is coupled to the second surface of the first layer and formed of a substantially flexible material. The vehicle panel also comprises a flap integrally formed with the main body portion at the edge and comprises at least the second layer. The vehicle panel further comprises a hinge separating the flap from the main body portion, the hinge is defined by at least a portion of the first layer having a reduced thickness. The flap is folded back about the hinge towards the first surface of the first layer to substantially conceal the edge. | 11-13-2014 |
Vaclav Tomasek, Praha CZ
Patent application number | Description | Published |
---|---|---|
20100189786 | CRYSTALLINE TOLTERODINE TARTARATE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A crystalline salt of 2-[(1R)-3-[bis(1-methylethyl)amino]- | 07-29-2010 |
20100261692 | METHOD OF MANUFACTURE OF COMPRESSED PHARMACEUTICAL FORMULATION CONTAINING TIBOLONE - Method of manufacture of compressed pharmaceutical formulation with the active substance tibolone by direct compression into tablets, whereas during the manufacturing process the formulation is subjected to the action of a protic solvent, either by addition of 0.1 to 3% by weight of said solvent in the liquid state and/or in the vapor form by ensuring the ambient atmosphere with the contents of solvent vapors above 50% relative. | 10-14-2010 |
20110038934 | PHARMACEUTICAL COMPOSITION WITH ATORVASTATIN ACTIVE INGREDIENT - A pharmaceutical composition containing the active substance atorvastatin in the form of oblong-shaped tablets with the length of 5 to 22 mm and the width of 2 to 11 mm or round tablets with the diameter of 3 to 16 mm, the core of which is constituted of compressed granulate and contains: i. Atorvastatin and/or at least one physiologically acceptable salt thereof in the quantity of 5 to 10% by weight, related to pure atorvastatin; ii. An organic or inorganic base selected from meglumine or an alkali metal hydroxide or their combination in the quantity of 0.01 to 7% by weight; iii. A pharmaceutically acceptable filler in the quantity of 20 to 90% by weight; iv. A disintegrant in the quantity of 0.5 to 50% by weight; provided with a coat that makes up 1 to 15% of the weight of the core, the selected base being uniformly distributed in the tablet core by means of spraying the same on the solid mixture in the granule production process. The composition can be obtained by a procedure consisting of the following steps: i. Mixing a mixture of atorvastatin, a filler and a disintegrant; ii. Dissolving a base in a mixture of water and a C | 02-17-2011 |
20110189295 | TELMISARTAN TABLETS - A composition containing the active substance telmisartan, which consists of granules of a telmisartan mixture, in which there is the active substance in the form of alkali salts, further contained is an organic or inorganic base selected from meglumine, sodium or potassium hydroxide, or a mixture of said bases, a binder, most preferably polyvinylpyrrolidone, sorbitol, and optionally other auxiliary substances; the composition further containing, outside the granules, particles of sorbitol, and optionally of other auxiliary substance, the size of 99% by\ weight of all particles of the telmisartan mixture being smaller than 1.0 mm and the size of 95% by weight of all particles of sorbitol contained in the composition inside as well as outside the granules of the telmisartan mixture being within the range of 0 to 0.250 mm. | 08-04-2011 |